Form 4: Axogen Director Joseph A. Tyndall Reports Acquisition of Shares and Stock Options

Director Joseph A. Tyndall reports acquisition of Axogen common stock and stock options as part of an annual equity grant.

Summary

• On June 6, 2024, Joseph A. Tyndall, a director of Axogen, Inc., reported the acquisition of 10,653 shares of common stock.
• These shares were acquired as restricted stock units.
• Tyndall also acquired 18,248 employee stock options with an exercise price of $7.04.
• These options are part of an annual equity grant for service as a Director on the Axogen, Inc. Board of Directors.
• The equity grant is valued at $150,000 as of the grant date.
• The restricted stock units and stock options vest on June 6, 2025, one year from the grant date.
• One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.

Future Outlook

The restricted stock units and stock options will vest on June 6, 2025, contingent on continued service as a director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings of company directors and their alignment with shareholder interests.

Stakeholder Impact

• The transaction aligns the director's interests with those of shareholders, as the value of the equity grant is tied to the company's stock performance.

Key Dates